Male breast cancer is a rare and little-known pathology. Its incidence is increasing in industrialized countries. There are many similarities with cancer in women, but there are also particularities in management, linked to patient age, the presence of co-morbidities, longer diagnosis times and smaller breast volume. Total mastectomy with axillary curage remains the gold standard. Sentinel node sampling is a promising option for early-stage management. Adjuvant irradiation is generally systematic, and tamoxifen remains the hormone therapy of choice. Adjuvant chemotherapy may be offered to high-risk patients. Overexpression of the HER2 oncoprotein, observed in 10-15% of patients, may justify the prescription of trastuzumab. Against the backdrop of the considerable progress achieved in recent years in the management of female breast cancer, we feel it is important to take stock of the data acquired and the possibility of exploiting these advances to improve the management of male breast cancer. Based on an observation of breast cancer, we review the clinico-radiological, therapeutic and prognostic aspects of this condition.
A Fri, study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: